Figure 1

H3-WT patients over-express EZHIP and cluster more closely to diffuse midline gliomas. (A) Relative expression of EZHIP (transcript per million (TPM)) in PFA-EPD, H3-WT midline gliomas and H3K27M DMG. (B) H&E and immunohistochemistry panel of zcc120 and zcc446 including H&E (400x, 600x, respectively), H3K27M (200x, 600x, respectively), H3K27me3 (200x, 600x, respectively) and EZHIP (400x, 600x, respectively). For zcc120 (left hand panels), immunohistochemical staining demonstrates negative nuclear staining for H3K27M mutant, loss of nuclear staining for H3K27me3 in tumour cells with preserved staining in inflammatory cells, and nuclear expression EZHIP in tumor cells. For zcc446 (right hand panels), immunohistochemical staining demonstrates negative nuclear staining for H3K27M mutant, loss of nuclear staining for H3K27me3 and absent EZHIP nuclear staining. (C) t-SNE unsupervised clustering of transcriptome profile and (D) methylation profile of all glioma tumours in the ZERO cohort. For a-c patients are highlighted as H3K27M DMG (N = 28; red), PFA-EPD in a and all EPD in b-c (N = 16; brown), LGG (N = 7; green), and HGG (N = 38; blue).